Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
July 19 2024 - 11:30AM
UK Regulatory
Half-Year Review of Inventiva’s Liquidity Contract with Kepler
Cheuvreux
Daix (France), Long Island City (New York, United
States), July 19, 2024 – Inventiva (Euronext Paris and
Nasdaq: IVA) (“Inventiva” or the
“Company”), a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of patients with metabolic dysfunction-associated
steatohepatitis (“MASH”), also known as
non-alcoholic steatohepatitis (“NASH”), and other
diseases with significant unmet medical needs, today announced the
half-year report of its liquidity contract with Kepler
Cheuvreux.
Under the liquidity contract granted to Kepler
Cheuvreux by Inventiva, the following resources were available in
the liquidity account as of June 30, 2023:
- Cash: € 285,764.46
- Number of shares: 129,659
- Number of executions on buy side on semester: 1,886
- Number of executions on sell side on semester: 1,610
- Traded volume on buy side on semester: 322,578 shares for €
1,074,534.26
- Traded volume on sell side on semester: 276,147 shares for €
938,985.90
At the last half-year report as of December 31,
2023, the following resources were available in the liquidity
account:
- Cash: € 416,331.34
- Number of shares: 83,228
- Number of executions on buy side on semester: 828
- Number of executions on sell side on semester: 877
- Traded volume on buy side on semester: 157,508 shares for €
584,045.97
- Traded volume on sell side on semester: 180,395 shares for €
695,421.23
When the contract was initially implemented, the
following resources were included in the liquidity account:
- Cash: € 163,510.42
- Number of shares: 34,063
|
Buy Side |
|
Sell Side |
|
Number of
executions |
Number of
shares |
Traded volume in EUR |
|
Number of
executions |
Number of
shares |
Traded volume in EUR |
Total |
1 886 |
322 578 |
1 074 534,26 |
|
1 610 |
276 147 |
938 985,90 |
01/02/2024 |
15 |
2 500 |
10 275,00 |
|
19 |
3 507 |
14 589,12 |
01/03/2024 |
5 |
1 000 |
4 140,00 |
|
2 |
1 000 |
4 190,00 |
01/04/2024 |
9 |
2 500 |
10 425,00 |
|
15 |
4 793 |
20 561,97 |
01/05/2024 |
11 |
2 463 |
9 999,78 |
|
- |
- |
- |
01/08/2024 |
5 |
1 500 |
6 165,00 |
|
10 |
3 373 |
13 997,95 |
01/09/2024 |
15 |
3 522 |
14 193,66 |
|
4 |
1 240 |
5 096,40 |
01/10/2024 |
12 |
2 978 |
11 971,56 |
|
5 |
1 024 |
4 126,72 |
01/11/2024 |
21 |
6 499 |
25 021,15 |
|
- |
- |
- |
01/12/2024 |
3 |
1 500 |
5 625,00 |
|
8 |
2 000 |
7 720,00 |
01/15/2024 |
15 |
3 500 |
12 705,00 |
|
2 |
282 |
1 026,48 |
01/16/2024 |
14 |
2 000 |
7 160,00 |
|
2 |
501 |
1 803,60 |
01/17/2024 |
23 |
3 427 |
11 891,69 |
|
2 |
192 |
683,52 |
01/18/2024 |
13 |
3 073 |
10 386,74 |
|
13 |
3 000 |
10 230,00 |
01/19/2024 |
2 |
500 |
1 700,00 |
|
6 |
1 250 |
4 275,00 |
01/22/2024 |
13 |
3 000 |
10 230,00 |
|
8 |
1 500 |
5 235,00 |
01/23/2024 |
3 |
1 500 |
5 115,00 |
|
16 |
4 716 |
16 694,64 |
01/24/2024 |
6 |
2 000 |
7 040,00 |
|
9 |
1 100 |
3 894,00 |
01/25/2024 |
8 |
1 500 |
5 265,00 |
|
1 |
1 |
3,56 |
01/26/2024 |
8 |
1 600 |
5 616,00 |
|
4 |
1 499 |
5 321,45 |
01/29/2024 |
10 |
1 000 |
3 530,00 |
|
7 |
2 054 |
7 291,70 |
01/30/2024 |
9 |
2 500 |
8 825,00 |
|
9 |
1 836 |
6 536,16 |
01/31/2024 |
12 |
2 751 |
9 600,99 |
|
10 |
1 302 |
4 570,02 |
02/01/2024 |
13 |
4 000 |
13 840,00 |
|
4 |
1 000 |
3 500,00 |
02/02/2024 |
13 |
3 001 |
10 293,43 |
|
5 |
1 030 |
3 574,10 |
02/05/2024 |
13 |
3 096 |
10 619,28 |
|
12 |
4 971 |
17 199,66 |
02/06/2024 |
19 |
2 904 |
9 931,68 |
|
7 |
2 000 |
6 900,00 |
02/07/2024 |
25 |
6 000 |
19 980,00 |
|
1 |
50 |
173,00 |
02/08/2024 |
8 |
1 500 |
4 875,00 |
|
10 |
1 314 |
4 296,78 |
02/09/2024 |
11 |
2 000 |
6 380,00 |
|
11 |
1 500 |
4 845,00 |
02/12/2024 |
13 |
1 750 |
5 810,00 |
|
31 |
8 636 |
29 103,32 |
02/13/2024 |
17 |
3 587 |
12 303,41 |
|
15 |
2 750 |
9 542,50 |
02/14/2024 |
12 |
2 250 |
7 807,50 |
|
18 |
3 629 |
12 737,79 |
02/15/2024 |
10 |
2 000 |
7 000,00 |
|
26 |
4 939 |
17 533,45 |
02/16/2024 |
44 |
10 663 |
31 882,37 |
|
13 |
2 500 |
7 625,00 |
02/19/2024 |
19 |
2 137 |
6 624,70 |
|
29 |
4 750 |
14 962,50 |
02/20/2024 |
25 |
3 613 |
11 091,91 |
|
7 |
1 001 |
3 123,12 |
02/21/2024 |
9 |
1 760 |
5 332,80 |
|
3 |
351 |
1 084,59 |
02/22/2024 |
13 |
1 721 |
5 231,84 |
|
2 |
251 |
773,08 |
02/23/2024 |
24 |
3 770 |
11 196,90 |
|
1 |
250 |
750,00 |
02/26/2024 |
15 |
2 250 |
6 592,50 |
|
12 |
2 250 |
6 660,00 |
02/27/2024 |
13 |
2 250 |
6 772,50 |
|
38 |
5 167 |
16 017,70 |
02/28/2024 |
14 |
2 010 |
6 130,50 |
|
21 |
3 732 |
11 755,80 |
02/29/2024 |
15 |
2 000 |
6 320,00 |
|
8 |
1 250 |
3 987,50 |
03/01/2024 |
12 |
2 029 |
6 492,80 |
|
20 |
3 500 |
11 410,00 |
03/04/2024 |
15 |
2 501 |
8 228,29 |
|
21 |
4 251 |
14 283,36 |
03/05/2024 |
23 |
3 500 |
11 725,00 |
|
28 |
2 308 |
7 916,44 |
03/06/2024 |
28 |
3 749 |
12 221,74 |
|
9 |
1 458 |
4 796,82 |
03/07/2024 |
14 |
1 573 |
5 112,25 |
|
12 |
2 500 |
8 250,00 |
03/08/2024 |
21 |
3 997 |
13 190,10 |
|
25 |
4 601 |
15 505,37 |
03/11/2024 |
16 |
2 250 |
7 560,00 |
|
20 |
2 999 |
10 196,60 |
03/12/2024 |
13 |
1 956 |
6 787,32 |
|
28 |
3 900 |
13 728,00 |
03/13/2024 |
10 |
1 530 |
5 355,00 |
|
24 |
2 500 |
8 875,00 |
03/14/2024 |
22 |
4 250 |
15 172,50 |
|
31 |
6 000 |
21 840,00 |
03/15/2024 |
16 |
2 000 |
7 320,00 |
|
39 |
4 750 |
17 622,50 |
03/18/2024 |
18 |
2 000 |
7 560,00 |
|
37 |
5 500 |
21 010,00 |
03/19/2024 |
101 |
20 564 |
75 881,16 |
|
34 |
6 863 |
28 550,08 |
03/20/2024 |
31 |
5 750 |
18 802,50 |
|
11 |
1 770 |
5 876,40 |
03/21/2024 |
2 |
500 |
1 635,00 |
|
43 |
5 730 |
19 596,60 |
03/22/2024 |
21 |
2 781 |
9 511,02 |
|
8 |
1 250 |
4 325,00 |
03/25/2024 |
12 |
1 750 |
6 055,00 |
|
14 |
1 750 |
6 142,50 |
03/26/2024 |
16 |
2 469 |
8 320,53 |
|
16 |
3 250 |
11 310,00 |
03/27/2024 |
32 |
5 000 |
17 050,00 |
|
5 |
1 250 |
4 400,00 |
03/28/2024 |
29 |
5 625 |
18 056,25 |
|
24 |
4 251 |
13 943,28 |
04/02/2024 |
14 |
2 750 |
9 047,50 |
|
11 |
1 829 |
6 108,86 |
04/03/2024 |
5 |
500 |
1 675,00 |
|
9 |
1 420 |
4 771,20 |
04/04/2024 |
12 |
2 000 |
6 680,00 |
|
8 |
1 500 |
5 085,00 |
04/05/2024 |
- |
- |
- |
|
8 |
500 |
1 685,00 |
04/08/2024 |
7 |
1 250 |
4 162,50 |
|
23 |
3 280 |
11 152,00 |
04/09/2024 |
9 |
1 210 |
4 198,70 |
|
20 |
3 720 |
13 131,60 |
04/10/2024 |
13 |
2 790 |
9 792,90 |
|
6 |
275 |
981,75 |
04/11/2024 |
29 |
4 001 |
13 683,42 |
|
2 |
24 |
82,56 |
04/12/2024 |
16 |
2 551 |
8 571,36 |
|
12 |
1 193 |
4 068,13 |
04/15/2024 |
42 |
4 949 |
16 282,21 |
|
21 |
4 503 |
15 040,02 |
04/16/2024 |
45 |
6 865 |
21 830,70 |
|
- |
- |
- |
04/17/2024 |
8 |
603 |
1 893,42 |
|
11 |
1 686 |
5 361,48 |
04/18/2024 |
10 |
1 997 |
6 370,43 |
|
8 |
1 264 |
4 070,08 |
04/19/2024 |
10 |
1 079 |
3 388,06 |
|
6 |
1 000 |
3 190,00 |
04/22/2024 |
8 |
1 000 |
3 170,00 |
|
5 |
500 |
1 600,00 |
04/23/2024 |
9 |
1 051 |
3 289,63 |
|
- |
- |
- |
04/24/2024 |
12 |
1 730 |
5 311,10 |
|
1 |
250 |
775,00 |
04/25/2024 |
4 |
740 |
2 227,40 |
|
4 |
444 |
1 367,52 |
04/26/2024 |
4 |
1 000 |
2 990,00 |
|
2 |
250 |
765,00 |
04/29/2024 |
15 |
2 001 |
5 902,95 |
|
19 |
1 319 |
3 930,62 |
04/30/2024 |
16 |
1 851 |
5 478,96 |
|
2 |
208 |
624,00 |
05/02/2024 |
4 |
524 |
1 566,76 |
|
17 |
2 993 |
9 008,93 |
05/03/2024 |
- |
- |
- |
|
46 |
7 114 |
22 053,40 |
05/06/2024 |
4 |
751 |
2 440,75 |
|
42 |
6 513 |
21 362,64 |
05/07/2024 |
8 |
1 503 |
4 989,96 |
|
20 |
3 250 |
10 920,00 |
05/08/2024 |
17 |
2 497 |
8 115,25 |
|
5 |
750 |
2 452,50 |
05/09/2024 |
9 |
1 749 |
5 649,27 |
|
3 |
175 |
570,50 |
05/10/2024 |
3 |
260 |
837,20 |
|
8 |
1 525 |
4 956,25 |
05/13/2024 |
19 |
2 763 |
9 421,83 |
|
56 |
9 234 |
31 764,96 |
05/14/2024 |
10 |
2 250 |
7 695,00 |
|
14 |
2 250 |
7 762,50 |
05/15/2024 |
8 |
1 000 |
3 470,00 |
|
18 |
3 054 |
10 689,00 |
05/16/2024 |
24 |
3 595 |
12 438,70 |
|
9 |
1 446 |
5 089,92 |
05/17/2024 |
14 |
1 850 |
6 586,00 |
|
38 |
5 835 |
21 006,00 |
05/20/2024 |
9 |
732 |
2 627,88 |
|
4 |
864 |
3 119,04 |
05/21/2024 |
8 |
1 279 |
4 578,82 |
|
8 |
1 250 |
4 487,50 |
05/22/2024 |
69 |
13 641 |
45 833,76 |
|
- |
- |
- |
05/23/2024 |
10 |
1 000 |
3 340,00 |
|
14 |
2 750 |
9 267,50 |
05/24/2024 |
12 |
1 921 |
6 339,30 |
|
9 |
1 500 |
5 010,00 |
05/27/2024 |
16 |
4 319 |
13 691,23 |
|
18 |
3 000 |
9 630,00 |
05/28/2024 |
12 |
1 289 |
4 111,91 |
|
5 |
1 001 |
3 203,20 |
05/29/2024 |
11 |
923 |
2 944,37 |
|
26 |
2 046 |
6 547,20 |
05/30/2024 |
2 |
427 |
1 357,86 |
|
8 |
1 250 |
4 050,00 |
05/31/2024 |
- |
- |
- |
|
18 |
3 750 |
12 637,50 |
06/03/2024 |
4 |
500 |
1 645,00 |
|
- |
- |
- |
06/04/2024 |
1 |
250 |
815,00 |
|
6 |
500 |
1 655,00 |
06/05/2024 |
12 |
751 |
2 463,28 |
|
2 |
2 |
6,60 |
06/06/2024 |
6 |
579 |
1 870,17 |
|
4 |
249 |
816,72 |
06/07/2024 |
5 |
671 |
2 147,20 |
|
- |
- |
- |
06/10/2024 |
18 |
1 560 |
5 023,20 |
|
23 |
4 413 |
14 342,25 |
06/11/2024 |
24 |
3 511 |
11 129,87 |
|
5 |
1 250 |
4 012,50 |
06/12/2024 |
50 |
7 534 |
22 526,66 |
|
3 |
486 |
1 535,76 |
06/13/2024 |
30 |
3 450 |
10 315,50 |
|
23 |
3 850 |
11 858,00 |
06/14/2024 |
39 |
5 700 |
16 131,00 |
|
1 |
250 |
750,00 |
06/17/2024 |
26 |
5 750 |
14 835,00 |
|
26 |
4 265 |
11 259,60 |
06/18/2024 |
16 |
2 680 |
6 834,00 |
|
12 |
1 600 |
4 128,00 |
06/19/2024 |
- |
- |
- |
|
20 |
5 432 |
14 938,00 |
06/20/2024 |
9 |
1 750 |
4 690,00 |
|
4 |
750 |
2 115,00 |
06/21/2024 |
- |
- |
- |
|
3 |
500 |
1 375,00 |
06/24/2024 |
- |
- |
- |
|
12 |
2 150 |
6 127,50 |
06/25/2024 |
22 |
3 545 |
10 138,70 |
|
7 |
912 |
2 663,04 |
06/26/2024 |
16 |
2 057 |
5 800,74 |
|
7 |
939 |
2 657,37 |
06/27/2024 |
4 |
500 |
1 415,00 |
|
11 |
1 761 |
5 071,68 |
06/28/2024 |
18 |
2 750 |
7 837,50 |
|
2 |
251 |
725,39 |
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH/NASH and
other diseases with significant unmet medical need. The Company
benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and
epigenetic modulation. Inventiva is currently advancing one
clinical candidate, has a pipeline of two preclinical programs and
continues to explore other development opportunities to add to its
pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with MASH/NASH, a
common and progressive chronic liver disease.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting a candidate for its Hippo signaling
pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937 |
Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Julia Cailleteau
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83 |
Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
Achats
Ventes
- Inventiva - PR - Liquidity Contract - S1 24 - EN - 19 07
2024
Inventiva (LSE:0RNK)
Historical Stock Chart
From Nov 2024 to Dec 2024
Inventiva (LSE:0RNK)
Historical Stock Chart
From Dec 2023 to Dec 2024